A Phase 1, Cross-Over, Single-Dose, Open-Label Study to Estimate the Relative Bioavailability of a Modified-Release Formulation of PF-05180999 Under Fed and Fasted Conditions in Healthy Adult Subjects.
Phase of Trial: Phase I
Latest Information Update: 29 Apr 2012
At a glance
- Drugs PF-5180999 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 29 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Apr 2012 Planned End Date changed from 1 Mar 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
- 20 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.